STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRNA
  4. [Form 4] Moderna, Inc. Insider Trading Activity

Moderna (NASDAQ: MRNA) awards director RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Moderna, Inc. director David M. Rubenstein reported new equity awards. On May 6, 2026, he received 2,092 restricted stock units, each convertible into one share of common stock.

He was also granted 9,681 stock options with an exercise price of $48.79 per share, expiring on May 6, 2036. Both the RSUs and options vest in full on the earlier of May 6, 2027 or Moderna's next Annual Meeting of Shareholders, subject to his continued service.

Positive

  • None.

Negative

  • None.
Insider Rubenstein David M.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 9,681 $0.00 --
Grant/Award Restricted Stock Units 2,092 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 9,681 shares (Direct, null); Restricted Stock Units — 2,092 shares (Direct, null)
Footnotes (1)
  1. This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Restricted stock units convert into common stock on a one-for-one basis. The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
RSU grant size 2,092 RSUs Granted on May 6, 2026 to director David M. Rubenstein
Option grant size 9,681 options Granted on May 6, 2026 to purchase common stock
Option exercise price $48.79 per share Conversion or exercise price for 9,681 stock options
Option expiration May 6, 2036 Expiration date of Rubenstein’s stock option award
RSU vesting date May 6, 2027 or next Annual Meeting Full vesting trigger for 2,092 RSUs, subject to continued service
Option vesting date May 6, 2027 or next Annual Meeting Full vesting and exercisability trigger for 9,681 options
RSUs after transaction 2,092 RSUs Total restricted stock units held following the award
Options after transaction 9,681 options Total stock options held following the award
Restricted Stock Units financial
"Restricted stock units convert into common stock on a one-for-one basis."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 48.7900."
vested and exercisable financial
"This option will become fully vested and exercisable on the earlier of May 6, 2027..."
Annual Meeting of Shareholders financial
"on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders..."
A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.
exercise price financial
"conversion or exercise price of 48.7900 for the stock option award."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rubenstein David M.
(Last)(First)(Middle)
C/O MODERNA, INC.
325 BINNEY STREET
(Street)
CAMBRIDGE MASSACHUSETTS 02142
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$48.7905/06/2026A9,681 (1)05/06/2036Common Stock9,681$09,681D
Restricted Stock Units(2)05/06/2026A2,092 (3) (3)Common Stock2,092$02,092D
Explanation of Responses:
1. This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
2. Restricted stock units convert into common stock on a one-for-one basis.
3. The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
/s/ James Dillon, As Attorney-in-Fact05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Moderna (MRNA) director David M. Rubenstein report?

David M. Rubenstein reported receiving equity awards from Moderna, not open-market trades. He was granted 2,092 restricted stock units and 9,681 stock options, both tied to his continued service and vesting by the earlier of May 6, 2027, or the next Annual Meeting.

How many RSUs did Moderna (MRNA) grant to director David M. Rubenstein?

Moderna granted David M. Rubenstein 2,092 restricted stock units. Each RSU converts into one share of common stock and will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, assuming he continues to serve.

What are the terms of David M. Rubenstein’s stock options from Moderna (MRNA)?

Rubenstein received 9,681 stock options with a $48.79 exercise price. These options become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, provided he continues his service, and they expire on May 6, 2036.

Do the Moderna (MRNA) Form 4 transactions involve stock being bought or sold on the market?

The Form 4 shows equity awards, not market purchases or sales. Rubenstein acquired RSUs and stock options as compensation, both granted at a reported price of $0.00 per unit, with vesting and exercisability dependent on his continued service as a director.

When will David M. Rubenstein’s Moderna (MRNA) RSUs and options vest?

Both the RSUs and options are scheduled to vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting. Vesting is subject to Rubenstein's continued service, aligning the awards' benefits with his ongoing role on the company’s board.